|Mr. Scott William Drake||Pres, CEO & Director||1.23M||N/A||1968|
|Mr. Shahriar Matin||Chief Operating Officer||671.21k||N/A||1975|
|Dr. James F. Dempsey||Chief Scientific Officer||468.31k||1.16M||1971|
|Mr. Zachary William Stassen||Chief Financial Officer||N/A||N/A||N/A|
|Ms. Michaella Gallina||VP. Chief of Staff and Head of Investor Relations & Communications||N/A||N/A||N/A|
|Mr. Robert McCormack||Sr. VP, Gen. Counsel & Corp. Sec.||N/A||N/A||N/A|
|Mr. Michael Saracen||VP of Marketing||N/A||N/A||N/A|
|Mr. Robert Michael Fuchs||Chief HR Officer||N/A||N/A||1967|
|Dr. Martin Fuss||Chief Medical Officer||N/A||N/A||N/A|
ViewRay, Inc. designs, manufactures, and markets radiation therapy systems. The company offers MRIdian, a magnetic resonance image guided radiation therapy system to image and treat cancer patients. Its MRIdian integrates MRI technology, radiation delivery, and proprietary software to see the soft tissues, shape the dose to accommodate for changes in anatomy, and strike the target using real-time targeting throughout the treatment. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers. ViewRay, Inc. markets its MRIdian through a direct sales force and distribution network. It has operations in the United States, France, Germany, and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.
ViewRay, Inc.’s ISS Governance QualityScore as of December 1, 2020 is 9. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 8; Compensation: 10.